PlainPill

Palmitoylethanolamide

People mainly take Palmitoylethanolamide for pain & inflammation, recovery, sleep. Based on 14 first-hand reports and 28 meta-analyses & systematic reviews in the medical literature. Ranked #555 of 1,974 overall.

25
User score
Mostly positive
29% positive0% mixed0% negative71% unclear

Of reports that state an outcome, 100% are positive.

Clinical research
AStrong research base
28
meta-analyses
69
RCTs
1,194
papers

What Palmitoylethanolamide does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found.

Nutrients · 2023 · Meta-analysis / systematic review
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials

Conclusion: The results of this systematic review and meta-analysis suggest that PEA is an effective and well-tolerated treatment for chronic pain. Further study is warranted to determine the optimal dosing and administration parameters of PEA for analgesic effects in the context of chronic pain.

PubMed 36986081 ↗
J Psychopharmacol · 2025 · Meta-analysis / systematic review
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities

Conclusion: This study underscores the efficacy and tolerability of several pharmacotherapies in managing agitation among children and adults with ASD or ID. Our findings provide robust evidence that specific treatments, such as arbaclofen, risperidone plus buspirone and omega-3 fatty acids, are both effective and well-tolerated, offering valuable therapeutic options for clinicians. The study emphasizes the need for ongoing research to ensure that treatment strategies remain aligned with the evolving clinical landscape, ultimately improving patient outcomes in this challenging population.

PubMed 39690490 ↗
Nat Prod Res · 2025 · Meta-analysis / systematic review
Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis

Conclusion: Six of these studies (199 patients) were included in the systematic review after the study selection process, and three studies for meta-analysia. Overall, PEA showed significant efficacy in reducing IOP in patients, this encourages its clinical use in glaucoma as well as across different forms of eye disorders.

PubMed 38269580 ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

occasionallyas reported
dailyas reported
6-8 weeks loadingas reported

Reported side effects

How often each side effect came up across all reports.

stomach issues ×1

What users say

Verbatim quotes, shortened only — each links to the original discussion.

“Then we are also releasing palmitoylethanolamide, which is a fatty acid amide.”
Source discussion ↗
“Palmitoylethanolamide should enhance the pain relief effects. Haven't tried it myself yet but will be ordering some soon”
Source discussion ↗
“it does appreciably decrease pain and inflammation...its ability to potentate cannabis/oleamide and decrease allergies, which happen after about a week”
Source discussion ↗
“Palmitoylethanolamide might be another good one.”
Source discussion ↗
“Palmitoylethanolamide, too. That will up-regulate GLT-1.”
Source discussion ↗
Top discussions (5)

Other options for pain & inflammation

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate